Our results revealed the pathogenicity of the SACS Val1335IIe mutation in the proband patient’s disease manifestation, even though the symptoms had a limited correlation with the typical ARSACS clinical triad, which could be due to the reduced chaperon function from haploinsufficiency. The gene discussed is SACS; the disease is Autosomal recessive spastic ataxia of Charlevoix-Saguenay.